Discovery STREAM

  1. RNA Delivery Business with Liberate's Shawn Davis, Ph.D. & Walter Strapps, Ph.D. 11/8/2023

    Earlier this year, Shawn Davis, Ph.D. left a pretty comfortable position at AstraZeneca (and Amgen before that, and Milliken – and others – before that) to lead Liberate Bio. He brought along another industry notable in Merck/Intellia alumnus Walter Strapps, Ph.D., who serves as CSO at Liberate. Why'd they do it? Because RNA delivery is such a crucial step toward revolutionary genetic medicine, but it's tough science. They think they can change that.

  2. Bio Career Moves With Codagenix's Johanna Kaufmann, Ph.D. 10/11/2023

    On this week's episode of the Business of Biotech, Dr. Johanna Kaufmann gives us an intimate retrospective on her career to date, sharing stories about her rapid ascension from Scientist 1 to executive leadership. We dig into her wild ride through M&A, her time at GSK, and the professional and personal development regimens she subscribes to.

  3. Saudi Arabia Government Leaders Discuss Agile Manufacturing Beyond Borders 10/23/2022

    Learn how government leaders in Saudi Arabia planned for biopharma resilience beyond borders and used agile manufacturing to prepare for the unknown.

  4. Bio & The Business Of Aging with Life Biosciences' Jerry McLaughlin 9/7/2023

    Core to the clinical-stage biopharma Life Biosciences belief set is that "contrary to popular belief, aging is not caused by random wear and tear, but instead is caused by a discrete set of biological mechanisms that can be targeted therapeutically.”

  5. BoB@JPM: Gene Writing With Tessera's Michael Severino, M.D. 2/26/2023

    Flagship Pioneering plucked Michael Severino, M.D. away from AbbVie to run point at Tessera, a startup it's backed to pioneer a new category of genetic medicine it calls gene writing. The Business of Biotech caught up with Severino at the JP Morgan Healthcare Conference in San Francisco last month. We learned what lured him away from leadership positions at Merck, Amgen, and AbbVie, how gene writing differs from gene therapy and gene editing, why the team at Tessera believes its technologies can write and rewrite DNA at the scales necessary to cure most genetic diseases, and where he plans to take the company from here. 

  6. LC/MS Method For Measurement In Human Plasma 2/17/2025

    According to the researchers, this plasma-based measurement has the potential to serve as a critical pharmacodynamic biomarker, facilitating the assessment of novel therapeutic approaches.

  7. Elucidating The Role Of IL-18 In NSCLC Integrated Analysis 1/23/2025

    Hear how imaging mass cytometry, CyTOF, and single-cell sequencing unlock the secrets of the tumor microenvironment. Discover new insights into IL-18 and its impact on non-small cell lung cancer.

  8. The NanoAssemblr® Spark™ Instrument Demo 4/13/2022

    The NanoAssemblr® Spark™ uses proprietary microfluidics technology for the controlled and reproducible manufacturing of nanoparticles in small volumes in less than 10 seconds.

  9. Is The Sensitivity Of Optical Biosensors Important? 2/17/2022

    Explore why the sensitivity of optical biosensors is important for not just small molecules or fragment-based interactions but also for larger molecular entities.

  10. Functional Antibody Screening With Abalone Bio's Richard Yu, Ph.D. 7/29/2025

    In this episode of "Better Biopharma," Abalone Bio's CEO and co-founder, Richard Yu, Ph.D., explains how the company's functional antibody selection technology (FAST) platform differs from traditional affinity screening.